IBIO
- iBio, Inc.
()
Overview
Company Summary
iBio, Inc. (IBIO) is a biotechnology company that specializes in developing and manufacturing plant-based pharmaceuticals and vaccines. The company utilizes a proprietary platform called "iBioLaunch" that enables the efficient production of biotherapeutic proteins, antibodies, and vaccines in plants.
iBio's technology is based on the use of tobacco plants, which are genetically engineered to express desired proteins. This platform offers several advantages over traditional methods of protein production, such as faster production times, lower costs, and increased scalability.
The company provides contract development and manufacturing services, collaborating with pharmaceutical and biotech companies that require large-scale production of their therapeutic proteins or vaccines. They support clients throughout the entire product development process, from early-stage research and development to commercial manufacturing.
iBio also has its own pipeline of product candidates, which includes biotherapeutics for the treatment of various diseases, including fibrosis, systemic sclerosis, and idiopathic pulmonary fibrosis. They are actively involved in the development of potential COVID-19 vaccine candidates as well.
Overall, iBio, Inc. aims to revolutionize the biopharmaceutical manufacturing industry by harnessing the power of plant-based production systems to create cost-effective and scalable solutions for the production of therapeutic proteins and vaccines.